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Background. Mesangial cells during embryonic development
and glomerular disease express smooth muscle a-actin (a-SMA).
We were therefore surprised when cultured mesangial cells
deprived of serum markedly increased expression of a-SMA.
Serum-deprived mesangial cells appeared larger than serum-fed
mesangial cells. We hypothesized that a-SMA expression may be
more reflective of mesangial cell hypertrophy than hyperplasia.
Methods. Human mesangial cells were cultured in medium
alone or with fetal bovine serum, thrombin, platelet-derived
growth factor-BB (PDGF-BB) and/or transforming growth fac-
tor-b1 (TGF-b1). a-SMA expression was examined by immuno-
fluorescence, Western blot, and Northern blot analysis. Cell size
was analyzed by forward light scatter flow cytometry.
Results. a-SMA mRNA was at least tenfold more abundant
after three to five days in human mesangial cells plated without
serum, but b-actin mRNA was unchanged. Serum-deprived cells
contained 5.3-fold more a-SMA after three days and 56-fold more
after five days by Western blot. Serum deprivation also increased
a-SMA in rat and mouse mesangial cells. The effects of serum
deprivation on a-SMA expression were reversible. Mesangial cell
mitogens, thrombin or PDGF-BB, decreased a-SMA, but TGF-b1
increased a-SMA expression and slowed mesangial cell prolifer-
ation in serum-plus medium. Flow cytometry showed that serum
deprivation or TGF-b1 treatment caused mesangial cell hypertro-
phy. PDGF-BB, thrombin, or thrombin receptor-activating pep-
tide blocked hypertrophy in response to serum deprivation.
Conclusions. We conclude that increased a-SMA expression in
mesangial cells reflects cellular hypertrophy rather than hyperpla-
sia.
Smooth muscle a-actin (a-SMA) is expressed in mesan-
gial cells in normal development [1–3] and in experimental
[4–9] and human [10, 11] glomerular disease, but little or
no a-SMA is expressed in normal adult mesangial cells in
vivo. Consequently, expression of a-SMA is considered a
marker of mesangial cell activation [7, 10–14]. Hyperplasia
and hypertrophy are two specific mesangial cell responses
that may result from mesangial cell activation [7]. Some
studies have shown that a-SMA correlates with mesangial
cell proliferation [4, 6, 9, 10], but other studies have found
exceptions to this correlation [8, 11, 15, 16].
Serum contains extracellular matrix proteins [17–19],
platelet factors [20–28], and other agents derived from
activation of coagulation (such as, thrombin) that poten-
tially regulate mesangial cell function in variety of ways. In
fact, products of platelet activation during coagulation are
responsible for the ability of serum to cause cell prolifera-
tion [21, 22]. Many of these same factors, either released by
platelets or produced by glomerular cells, are thought to be
important mediators of disease and responsible for mesan-
gial cell activation.
Factors responsible for the expression of a-SMA in
glomerular disease are poorly understood. a-SMA expres-
sion was associated with increased expression of platelet-
derived growth factor (PDGF) and/or PDGF receptor in
some investigations [6, 7, 29]. In vitro studies are also
limited. In one study, growth arrest of rat mesangial cells
for seven days in serum-free medium did not change the
percentage of a-SMA positive cells [30]. In another study,
serum stimulated transcription of a reporter gene fused to
a sequence spanning 2894 to 11 of the a-SMA promoter
in transfected rat mesangial cells [12], but the effect of
serum directly on a-SMA was not determined. In another
study, the role of the serum response element in regulating
a-SMA gene expression in rat mesangial cell hillocks was
recently examined [31]. These investigators found that both
the expression of smooth muscle actin and the activity of a
b-galactosidase reporter were decreased in hillocks com-
pared to surrounding cells. a-SMA mRNA and reporter
mRNA were also decreased when cells were embedded in
collagen gels. All of these studies suggested that serum
should increase a-SMA in routinely cultured mesangial
cells.
Recently, we showed that human mesangial cells survive
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for several weeks in medium without serum or added
growth factors [32]. We expected serum deprivation to
cause a loss of a-SMA expression. In contrast to our
expectations, serum deprivation increased a-SMA expres-
sion by an order of magnitude. The effects of PDGF-BB,
thrombin and transforming growth factor b1 (TGF-b1)
were also investigated. PDGF-BB and thrombin are mito-
genic in human mesangial cells [33] and, like serum,
inhibited a-SMA expression. TGF-b1 is anti-proliferative in
mesangial cells [34] and stimulated a-SMA expression. By
flow cytometry, increased cell size accompanied increased
a-SMA expression. These observations suggest that in-
creased a-SMA expression in disease may be evidence of
mesangial cell hypertrophy rather than hyperplasia.
METHODS
Materials
Antibody to a-SMA (clone 1A4) was from Sigma Chem-
ical Co. (St. Louis, MO, USA). Recombinant PDGF-BB,
recombinant TGF-b1 and monoclonal antibody to
PDGF-BB were from R&D Systems (Minneapolis, MN,
USA). Thrombin was a gift of Dr. J. Fenton (Wadsworth
Center Labs, Albany, NY, USA). Complementary DNA
probes used in these studies were a-SMA, graciously given
by Dr. C. Chandra Kumar (Schering-Plough Research
Institute, Kenilworth, NJ, USA) and b-actin [35] (ATCC
#37997), glyceraldehyde phosphate-3-dehydrogenase
(GAPD) [36] (ATCC#57091), and 18S ribosomal RNA
[37] (ATCC# 77242) from The American Type Culture
Collection (Rockville, MD, USA).
Cell culture
Human mesangial cells were isolated as described [32].
The cells were routinely grown in RPMI 1640 with fetal
bovine serum (FBS 5:1) without antibiotics or other addi-
tives and were used during the first 10 passages. Serum-free
cells were prepared by washing three times and resuspend-
ing in RPMI 1640 prior to plating. Rat mesangial cells were
isolated by us as described [32] from the kidneys of
Sprague-Dawley rats sacrificed for hepatectomy [38] in the
laboratory of Dr. Steven L. Gonias (Department of Pathol-
ogy, University of Virginia Health Sciences Center). Rat
mesangial cells were positive for Th1.1 by both indirect
immunofluorescence and Western blot. Mouse mesangial
cells from non-diabetic NOD mice [39] were a gift of Dr.
Oleh Pankewycz (Department of Medicine, University of
Virginia Health Sciences Center).
Typical plating conditions included: (1) in RPMI 1640
with 16.7% (5:1 dilution) serum, (2) in RPMI 1640 without
other additives, but onto serum-coated substrata, or (3) in
RPMI 1640 alone onto non-coated substrata. Cells were
plated on serum-coated (condition 2) and non-coated
(condition 3) coverslips to compare the effects of different
substrata on a-SMA expression. Under both conditions,
cells become fully growth arrested after about one week
[32]. On serum-coated substrata, adhesion at focal contacts
is mediated via vitronectin receptors, but on non-coated
substrata adhesion at focal contacts is mediated by fi-
bronectin receptors [32].
RNA preparation and Northern blot
Total RNA was extracted using TRIzol reagent from
Gibco BRL (Gaithersburg, MD, USA) and analyzed using
ultraviolet spectrophotometry at 260 and 280 nm. The
A260/A280 ratios of all samples used for Northern blot
analysis were between 1.6 and 2.0. RNA samples (10 mg per
lane) were denatured with glyoxal and electrophoretically
separated in a 1.2% agarose gel [40]. The RNA was
electrophoretically transferred to a nylon membrane and
UV-crosslinked. The blots were prehybridized in 50%
formamide, 5 3 SSPE, 5 3 Denhardt’s, 1 mg/ml salmon
testes DNA, and 0.5% SDS and then hybridized in the
same solution containing 4% dextran sulfate and one or
more labeled cDNA probes. Probes were labeled with
[a-32P]d-cytidine triphosphate by random primer labeling
using a commercially available kit from Gibco BRL. The
hybridization temperature was 42°C for all probes used.
The blots were washed twice in 5 3 SSPE/0.5% SDS at
25°C and then twice in 0.5 3 SSPE/1% SDS at 65°C. A 0.24
to 9.5 kb ladder from Gibco BRL was used for molecular
size determinations. The signal was detected by phospor-
imaging, and the bands were quantified using ImageQuant
software. When necessary, the membrane was hybridized
after washing again at 100°C in water for 30 minutes.
Immunofluorescence
Immunofluorescence was performed as previously de-
scribed [32]. In brief, cells on coverslips were inverted onto
diluted antibodies overnight. The coverslips were subse-
quently incubated with biotinylated secondary antibody and
then with Texas Red-avidin and bodipy-phallacidin, to-
gether. The coverslips were mounted in Gelvatol [41]. Cells
were photographed using Kodak ecktachrome 400 film with
an Olympus BH-2 microscope equipped for epifluores-
cence.
Western blot
Western blot analysis was performed as described previ-
ously [32]. To summarize, reduced proteins were trans-
ferred from gels to PVDF membranes from Millipore
(Bedford, MA, USA) essentially as described by Towbin,
Staehelin and Gordon [42]. a-SMA on membranes was
stained using alkaline phosphatase-avidin-biotin complex
(ABC) according to the manufacturer’s instructions (Vec-
tor Laboratories, Inc., Burlingame, CA, USA). Blots were
developed with NBT-BCIP, BioRad (Hercules, CA, USA),
prepared according to instructions.
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Analysis of mesangial cell size by flow cytometry
Mesangial cells were plated in 100-mm dishes in RPMI
1640 with serum at 200,000 cells/dish or 106 cells/ml. Cells
plated at the latter density were changed to medium
without serum after four hours. Cells in medium with
serum received either no addition (1serum) or 10 ng/ml
TGF-b1 (1serum, 1TGF-b1). Cells in RPMI 1640 without
serum received either no addition (-serum), 10 ng/ml
TGF-b1 (2serum, 1TGF-b1), 10 ng/ml PDGF-BB (2se-
rum, 1PDGF-BB), both PDGF-BB and TGF-b1 (2serum,
1PDGF, 1TGF-b1), 10 nM thrombin (2serum, 1throm-
bin), or 200 mM thrombin receptor-activating peptide (2se-
rum, 1SFLLRN). These agents were added on days 0, 2,
and 5 after plating. On day 7 the cells were released with
trypsin and resuspended in 10 ml of RPMI 1640 with FBS.
The cells were placed on ice. Aliquots of the cells were
counted using a Coulter Counter. The cells were centri-
fuged at 600 3 g at 4°C for five minutes and resuspended at
a concentration of 106 cells/ml. The cells were returned to
ice and then analyzed with a Becton Dickinson Facscan
fluorescence-activated cell sorter using forward light scatter
mode. Results were obtained as plots of number of cells
versus cell size (proportional to cell surface area) in
arbitrary units. Cells not used for flow analysis were rinsed
twice in PBS and extracted for Western blot analysis of
a-SMA.
Preparation of images
Images prepared from blots or photomicrographs of
fluorescence microscopy were printed on a Epson Stylus
Color 600 printer. Original blots or ektachrome slides were
scanned with either a LaCie flatbed scanner or Nikon film
scanner using Adobe Photoshop software. Densitometric
measurements of Western blot band densities (arbitrary
units) were determined using NIH Image software version
1.59 by Wayne Rasband. All images of a particular exper-
imental condition, blot or gel were processed identically
unless stated otherwise.
RESULTS
Expression of a-smooth muscle actin in serum-deprived
mesangial cells
Increased a-SMA expression has been observed to ac-
company mesangial cell proliferation in glomerular disease
[4, 6, 9, 10]. Based on this observation, we hypothesized
that serum-deprivation would arrest proliferation and
cause loss of a-SMA expression in cultured mesangial cells.
Human mesangial cells were plated under three conditions
to test this hypothesis: in medium with serum, and in
medium without serum on either serum-coated or non-
coated coverslips. Figure 1 shows the effect of plating cells
with or without serum on a-SMA expression after three
days. The cells were fixed with paraformaldehyde and
double-labeled with bodipy-phallacidin and a-SMA-spe-
cific antibody (indirect immunofluorescence; Texas Red).
Phallacidin binds to filamentous actin (f-actin) of any type
but not to globular actin (g-actin) [43]. Mesangial cells in
serum were small and often spindle-shaped, but cells in
serum-free medium were broad and polygonal. In serum,
the actin filaments were thinner and less abundant (Fig.
1A) than in serum-free medium (Fig. 1 C, E). Contrary to
our hypothesis, mesangial cells in RPMI 1640 with serum
stained very weakly, if at all, for a-SMA by immunofluo-
rescence, but mesangial cells in RPMI 1640 alone stained
universally and intensely. Cells in serum-free medium
expressed a-SMA regardless of whether they were plated
onto serum-coated (Fig. 1D) or non-coated (Fig. 1F) glass
coverslips.
The reversibility of the effects of serum deprivation on
a-SMA expression was investigated by both Northern and
Western blotting (Fig. 2). Cells were washed and plated in
100 mm culture dishes either in medium with serum or
without serum. Three days after plating, cells in some of the
dishes were released with trypsin, washed, and extracted for
analysis of mRNA and protein. Media were changed on the
remaining dishes. Some were continued in the same type of
medium, either RPMI 1640 with 16.7% FBS (serum-plus)
or without FBS (serum-minus), but others were changed
from either serum-plus to serum-minus or from serum-
minus to serum-plus. Two days later the remaining dishes
were extracted. Figure 2A shows hybridization with probes
for a-SMA, b-actin, GAPD and 18S ribosomal RNA.
Equal amounts of RNA were analyzed. Marked differences
in a-SMA mRNA levels were immediately apparent be-
tween cells in medium with or without serum. Band inten-
sities were quantified using a phosphor-imager. Relative
band intensities (summarized in Table 1) were normalized
to their values in serum on day 3 (S1). b-actin, GAPD, and
18S RNA differed in other lanes by twofold or less, but
a-SMA mRNA increased tenfold with serum deprivation
for three days or five days. Two days after changing the
medium from serum-minus to serum-plus (S2 . S1), the
level of a-SMA mRNA decreased from 10.6-fold to only
2.2-fold of the level in S1 cells on day 3. Therefore, the
effects on a-SMA expression of adding or removing serum
could be reversed.
One dish each of cells treated as in Figure 2 was
extracted for analysis of a-SMA by Western blot (Fig. 2B).
Serum-plus medium decreased a-SMA protein levels as it
did mRNA levels. After three days, the a-SMA band
density in serum-minus cells (S2) was 5.3-fold its density in
serum-plus cells (S1). The level of a-SMA protein contin-
ued to decline in serum-plus medium, and after five days
(S1 . S1), was only one fifth of its level after three days
(S1). The band density of a-SMA from cells serum-minus
for five days (S2 . S2) was 56-fold that of cells serum-plus
for five days (S1 . S1). In 16 of 16 experiments, cells in
medium with serum for one to three days contained
markedly less a-SMA than cells in medium without serum.
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Expression of a-smooth muscle actin in serum-deprived
rat and mouse mesangial cells
Many published studies of a-SMA expression in disease
have involved animal models, primarily rats. Figure 3
compares expression of a-SMA by rat and mouse mesan-
gial cells treated as in Figure 2 in serum-plus and serum-
minus medium. Interestingly, expression of a-SMA in these
species in the presence of serum greatly exceeded the
expression of a-SMA in human mesangial cells in serum.
Nonetheless, expression of a-SMA was less in the presence
of serum than in serum-free medium. Similar results were
obtained by immunofluorescence (not shown).
Effect of platelet derived growth factor-BB and thrombin
The abilities of two serum constituents, PDGF-BB and
thrombin, to affect a-SMA expression in human mesangial
cells were determined. Figure 4 shows that two days after
adding thrombin the band density of a-SMA by Western
blot was about 50% of control, and after adding recombi-
nant human PDGF-BB, the level was about 40% of control.
PDGF-BB decreased a-SMA expression by Western blot in
8 of 8 experiments, and thrombin decreased it in 6 of 7
experiments. The effects of these agents on a-SMA mRNA
levels were also determined. RNA was extracted at 0, 4, 8,
and 24 hours after the addition of either thrombin or
Fig. 1. Fluorescence staining of total F-actin and a-smooth muscle actin (a-SMA) in human mesangial cells. Human mesangial cells were washed and
plated (40,000 cells/well) in RPMI 1640 with (A and B) and without (C through F) 16.7% serum onto non-coated (A, B, E, F) and serum-coated glass
coverslips (C, D). Three days after plating, the cells were fixed and double-labeled with bodipy-phallacidin (A, C, E) for total f-actin and by indirect
immunofluorescence (Texas Red) for a-SMA (B, D, F). Bar 5 116 mm.
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PDGF-BB and analyzed by Northern blot (Fig. 5). Band
intensities were quantified using a phosphor-imager. Rela-
tive band intensities (summarized in Table 2) were normal-
ized to the values at time 0. The effects of thrombin and
PDGF-BB on a-SMA mRNA followed a similar time
course. The a-SMA mRNA level declined slightly in the
first eight hours, and after 24 hours was about one-fifth of
control (0 hr) in both cases.
Effect of transforming growth factor-b1
Transforming growth factor-b has been reported to
stimulate a-SMA expression in smooth muscle cells [44]
Fig. 2. Effect of serum or a-SMA mRNA in
human mesangial cells by Northern and
Western blots. Cells were plated either in
medium with serum (S1) at 200,000 cells/100
mm dish or without serum in non-coated dishes
(S2) at 106 cells/100 mm dish. Three days after
plating RNA (5 dishes) and protein (one dish)
were extracted from some dishes in each group
(S1, S2). The medium was changed on the
remaining dishes. Six dishes for each condition
were continued in the same medium, either
with serum (S1 . S1) or without serum (S2
. S2). Six dishes for each were changed from
medium with serum to medium without serum
(S1 . S2) or from medium without serum to
medium with serum (S2 . S1). On day 5,
RNA and protein were extracted from the
remaining dishes. The RNA (10 mg/lane) was
analyzed by Northern blot with cDNA probes
for a-SMA and b-actin, and then stripped and
reprobed for GAPD, followed by 18S ribosomal
RNA (A). Quantified results are summarized in
Table 1. One dish each of cells treated as
described above was extracted and analyzed by
Western blot for a-SMA (B). Band densities in
arbitrary units determined using NIH Image
Software are shown below each a-SMA band.
Table 1. Relative levels of a-smooth muscle actin (a-SMA) mRNA in mesangial cells in serum-plus (S1) and serum-minus (S2) medium
determined by Northern blot (Fig. 2) normalized to their values in serum-plus cells on day 3
S1 S1 . S1 S1 . S2 S2 S2 . S2 S2 . S1
Day 0 serum 1 serum 1 serum 1 serum 2 serum 2 serum 2
Day 3 extract serum 1 serum 2 extract serum 2 serum 1
Day 5 extract extract extract extract
b-actin 1.0 1.0 0.7 0.6 0.5 0.9
a-SMA 1.0 1.3 7.0 10.6 10.7 2.3
GAPD 1.0 1.5 0.8 0.6 0.5 1.2
18S 1.0 1.0 0.9 0.9 1.0 1.0
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and fibroblasts [45]. The hypothesis that TGF-b1 increases
a-SMA expression in human mesangial cells was tested.
Cells in either serum-plus or serum-minus medium for
three days were treated with 10 ng/ml TGF-b1 for two days.
Next the cells were extracted and analyzed by Northern blot
for b-actin, a-SMA, GAPD, and 18S ribosomal RNA (Fig.
6A). Analysis by phosphor imaging, summarized in Table 3,
revealed that TGF-b1 caused about a threefold (range 2.4-
to 4.0-fold) increase in the a-SMA mRNA level in the
presence of serum, but had little or no effect on the a-SMA
mRNA level in serum-minus cells. Although the initial
intent had been to normalize the data to GAPD or 18S
RNA, the levels of these RNA species were noted to
decrease with serum deprivation to varying degrees in
different experiments. In this experiment, with samples
prepared in triplicate, serum-minus cells contained about
one-fifth as much GAPD mRNA and about one-third as
much 18S RNA as serum-plus cells. The cause for the
observed variability in the effects of serum deprivation on
GAPD and 18S RNA is not known. However, within either
serum-plus or serum-minus conditions, none of the agents
studied (thrombin, PDGF, and TGF-b1) appeared to affect
GAPD or 18S levels. Nonetheless, in response to serum
deprivation, these RNA species decrease while a-SMA
mRNA increases. Consequently, normalization of the data
to either of theses species would indicate even greater
increases (about 30- to 60-fold) in a-SMA mRNA levels
due to serum deprivation.
Extracts of cells from the same experiment were ana-
lyzed by Western blot for a-SMA (Fig. 6B). a-SMA
protein, like its mRNA, increased in cells treated with
TGF-b1 in medium with serum, about two-fold, but did not
increase in cells treated in medium without serum.
Regulation of cell size and a-smooth muscle actin
expression
Transforming growth factor-b stimulates a-SMA expres-
sion in smooth muscle cells [44] and fibroblasts [45], and
causes hypertrophy of rat mesangial cells [46]. Human
mesangial cells in RPMI 1640 alone appeared larger than
mesangial cells in serum (Fig. 1). These observations
suggested that the serum-free mesangial cells underwent
hypertrophy. The possibility that agents that alter mesan-
gial cell a-SMA content also alter cell size was investigated
by analyzing mesangial cells with a Becton Dickinson
Facscan fluorescence-activated cell sorter using forward
light scatter mode. The cells were treated three times over
the course of a week with fresh medium containing either
no additional agent or 10 ng/ml TGF-b1, 10 ng/ml PDGF-
BB, 10 nM thrombin or 200 mM SFLLRN peptide, alone or
in combination. At the end of one week, the cells were
harvested by trypsinization and analyzed. Figure 7 shows
graphically the distribution of mesangial cell sizes under
Fig. 3. Effect of serum on a-SMA protein in rat and mouse mesangial
cells by Western blot. Rat and mouse mesangial cells were cultured and
the cells were treated as described in Figure 2. Lane numbers and legends
are the same as Figure 2.
Fig. 4. Western blot analysis of the effects of thrombin and PDGF-BB on
a-SMA. Washed cells (200,000 cells/well of 6-well plates) were plated in
RPMI 1640 without serum. Five days after plating, the cells were changed
to fresh RPMI 1640 alone (control) or containing either 5 nM thrombin or
10 ng/ml PDGF-BB. After seven days the cells were extracted in electro-
phoresis sample buffer and analyzed by Western blot (2 mg/lane). Extracts
from three wells per condition are shown.
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each condition. Cells from the same experiment were
extracted and analyzed by Western blot for a-SMA (Fig. 8).
Regardless of the agent added, cells in serum-minus me-
dium contained more a-SMA than cells in serum-plus
medium. To avoid saturated staining (as in Fig. 6), less
protein extracted from cells treated under serum-minus
conditions (0.2 mg, panels/lanes C-H) than serum-plus
conditions (1 mg, panels/lanes A, B) was analyzed by
Western blot. In each case, cellular enlargement was ac-
companied by increased a-SMA expression. Cells plated
without serum (panel/lane C) were larger and contained
more a-SMA than cells plated with serum (panel/lane A).
Cells treated with TGF-b1 in serum-plus medium (panel/
lane B) were larger and contained more a-SMA than cells
in serum-plus medium alone (panel/lane A). The addition
of TGF-b1 to serum-minus cells (panel/lane D) had no
effect on either cell size or a-SMA content compared to
serum-minus cells alone (panel/lane C). PDGF-BB pre-
vented enlargement of mesangial cells in serum free me-
dium (Fig. 7E) and antagonized a-SMA expression (Fig. 8,
lane E). Cells treated with both PDGF-BB and TGF-b1
(panel/lane F) contained an amount of a-SMA intermedi-
ate between that of cells treated with either PDGF-BB
(panel/lane E) or TGF-b1 (panel/lane D) alone. Thrombin
(panel/lane G), like PDGF-BB, reduced mesangial cell size
and a-SMA content compared to serum-minus medium
alone (panel/lane C). Thrombin receptor-activating peptide
(SFLLRN) also decreased the size and actin content of
mesangial cells (panel/lane H), but to a lesser extent than
thrombin.
The effect of TGF-b1 and PDGF-BB in combination was
further investigated. Three separate experiments were
done following the same experimental protocol as above,
but varying the concentration of PDGF-BB. Both forward
light scattering and a-SMA expression were analyzed. The
results of each experiment were normalized to the values
for serum-minus cells (defined as 100%) and ranged from
80% to 127%. Figure 9 shows average results from the
three experiments. Although absolute values varied be-
tween experiments, the trends shown were present in each
experiment. Cells in serum-plus medium were smallest
(88%) and contained the least amount of a-SMA. Cells
treated with TGF-b1 in the presence of serum were the
largest, and on average, contained four times as much
a-SMA. Cells in serum-minus medium contained the most
a-SMA, about 20 times as much as serum-plus cells; the
addition of TGF-b1 to serum-minus cells had little effect on
cell size or a-SMA expression. Addition of PDGF-BB to
serum-minus medium caused a dose-dependent decrease in
cell size and a-SMA expression that was offset by addition
of TGF-b1. The effect of TGF-b1 appeared greater at lower
PDGF-BB concentrations.
DISCUSSION
Our studies show that expression of a-SMA mRNA and
protein in cultured mesangial cells correlates better with
hypertrophy rather than proliferation. Human mesangial
cell mitogens (serum, PDGF-BB [33] and thrombin [33])
inhibited a-SMA expression and antagonized hypertropy.
Conditions that inhibited proliferation (TGF-b1 [34] or
serum-free medium) increased a-SMA expression and
caused hypertrophy.
Fig. 5. Expression of a-SMA mRNA in
mesangial cells in serum-free medium
containing thrombin or PDGF. Washed cells
(106 cell/100 mm dish) were plated without
serum. Three days after plating, the cells were
treated with either 10 nM thrombin or 10 ng/ml
PDGF-BB. RNA was extracted from the cells
after 0 hours (0), four hours (4), eight hours
(8), and 24 hours (24). The RNA (10 mg/lane)
was analyzed by Northern blot with cDNA
probes for a-SMA and b-actin, and then
stripped and reprobed for GAPD, followed by
18S ribosomal RNA. Quantified results are
summarized in Table 2.
Table 2. Relative levels of a-SMA mRNA in mesangial cells treated
with thrombin or PDGF-BB determined by Northern blot (Fig. 5)
normalized to their values at time 0
Time
Thrombin 10 nM PDGF-BB 10 ng/ml
0 hr 4 hr 8 hr 24 hr 0 hr 4 hr 8 hr 24 hr
b-actin 1.0 0.8 1.6 0.5 1.0 1.2 1.1 0.8
a-SMA 1.0 0.9 0.6 0.2 1.0 0.9 0.3 0.2
GAPD 1.0 1.0 0.7 0.7 1.0 0.9 0.4 0.5
18S 1.0 1.0 1.1 1.2 1.0 0.9 0.8 0.9
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The finding that serum deprivation increases a-SMA
protein and mRNA levels was surprising given the results
of studies using reporter constructs that contain a-SMA
promoter regions [12, 31]. The rat promoter contains two
CC(A/T)6GG sequences (CArG box elements) responsible
for binding of serum response factor. Thus, one would
expect that a-SMA mRNA transcription would be in-
creased in medium containing serum compared to medium
without serum. Nevertheless, the effect of serum depriva-
tion on a-SMA mRNA and protein is not described in
either of these papers. One possible explanation for our
unexpected finding is that although serum increases
a-SMA transcription, it increases a-SMA mRNA degrada-
tion to a greater extent. Thus, serum deprivation may
increase a-SMA mRNA and protein levels even though it
decreases a-SMA transcription by a compensatory increase
in a-SMA message stability. This is currently under inves-
tigation.
Conversion of plasma to serum endows it with its mito-
genic properties [21, 22]. The factors are probably diverse;
however, PDGF isoforms have probably been the best
studied. PDGF activity in serum varies widely between
species. In one study, human serum contained 13.3 6 4.5
ng/ml total PDGF activity (6.25 6 2.2% BB isoform) while
FBS contained 0.93 6 0.3 ng/ml (82 6 12% BB isoform)
[47]. The mitogenic potency of human and bovine sera were
similar despite these differences, suggesting that other
substances were as important as PDGF in giving serum its
Fig. 6. Effect of TGF-B1 on a-SMA in human mesangial cells by Northern and Western blots. Mesangial cells were plated at a density of either
400,000/100 mm dish (6 dishes) in RPMI 1640 plus serum or at 2 3 106/100 mm dish (6 dishes) in RPMI 1640 alone. After three days, the cells were
treated with fresh medium (serum-minus or serum-plus) with or without 10 ng/ml TGF-B1 for two days. The cells were detached with trypsin and cells
from duplicate dishes were pooled and extracted, giving triplicate samples for each condition. The RNA (10 mg/lane) was analyzed by Northern blot
with cDNA probes for a-SMA and b-actin, and then stripped and reprobed for GAPD, followed by 18S ribosomal RNA. Quantified results are
summarized in Table 3. An aliquot of cells from each sample was extracted in electrophoresis sample buffer and 5 mg protein/lane was analyzed by
Western blot (B).
Table 3. Relative levels of a-SMA mRNA in mesangial cells treated
with TGF-b1 determined by Northern blot (Fig. 6) in triplicate
normalized to their average values in serum-plus medium without TGF-
b1
TGF-
b1
Serum-plus Serum-minus
2 2 2 1 1 1 2 2 2 1 1 1
b-actin 0.9 0.8 1.2 1.0 0.9 1.2 0.8 0.5 0.8 0.7 0.9 0.9
aSMA 1.1 0.7 1.2 2.9 2.4 4.0 12.8 7.9 9.4 9.9 13.6 12.4
GAPD 1.0 0.8 1.1 0.7 0.6 0.9 0.2 0.1 0.2 0.2 0.3 0.2
18S 1.1 0.9 1.0 0.8 0.7 0.9 0.4 0.3 0.4 0.4 0.5 0.6
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Fig. 7. Forward light scatter flow cytometry of human mesangial cells treated with TGFb1, PDGF-BB, thrombin, and/or SFLLRN. Cells were in RPMI
1640 with (A and B) or without serum (C through H) containing no addition (A), 10 ng/ml TGFb1, (B, D, and F), 10 ng/ml PDGF-BB (E and F), 10
nM thrombin (G) and/or 200 mM SFLLRN-peptide (H). Media containing the appropriate agent(s) were changed twice and the cells were released with
trypsin and analyzed after one week. The vertical line provides a reference for comparison to the position of the peak in cells grown in medium with
serum (A). The number of cells counted (y-axis; 15 cells/division) is plotted against cell size (x-axis; arbitrary units). The median cell size (arbitrary units)
is noted for each condition.
mitogenic properties. These unidentified substances could
also affect a-SMA expression and mesangial cell size.
Thrombin is present in serum. Whether thrombin con-
tributes significantly to the mitogenic activity of serum is
unclear because of the abundance of protease inhibitors in
serum. However, the active concentration of thrombin in
fresh 10% FBS was 10 ng/ml (0.3 nM) and after three days
at 37°C, it was 28 ng/ml (0.8 nM) in one investigation [48].
Our experiments were conducted with 5 to 10 nM thrombin.
PDGF-BB and/or thrombin may contribute to inhibition of
a-SMA expression by serum, but inhibition of a-SMA
expression by serum is probably the sum of diverse compo-
nents.
Thrombin causes mesangial cells to secrete PDGF [33],
and thus, inhibition of a-SMA expression by thrombin
might have been the result of autocrine stimulation by
PDGF. However, neutralizing-antibody to PDGF-BB (also
PDGF-AB) did not block the effect of thrombin on a-SMA
expression at concentrations in excess of that necessary to
block 10 ng/ml PDGF-BB (not shown). Hence, the effect of
thrombin on a-SMA expression seems to be independent
of PDGF-BB secretion.
If a similar relationship between hypertrophy and
a-SMA expression in mesangial cells exists in vivo, then
expression of a-SMA in conditions where there is little
proliferation can be explained. For example, angiotensin II
caused increased expression of a-SMA in the mesangial
cells of treated rats without causing mesangial cell
proliferation [8]. Increased expression of a-SMA has
been observed in human [11] and experimental diabetic
glomerular injury [49]. The authors of the latter study
[49] suggested that increased expression of contractile
proteins in such diseases might serve as a marker for
glomerular hypertrophy. Thus, expression of a-SMA
under these in vivo conditions may indicate mesangial
cell hypertrophy.
Cells may undergo hyperplasia and hypertrophy simulta-
neously. TGF-b1 caused mesangial cell hypertrophy and
increased a-SMA expression in serum-plus medium with-
out fully antagonizing the hyperplastic response of the cells
to serum (Fig. 8). After one week, the dish with serum-plus
medium alone contained 16-times as many cells as plated,
while the dish with serum-plus medium and 10 ng/ml
TGF-b1 contained 10 times as many cells as plated. There-
fore, cells in serum-plus medium with TGF-b1 underwent
hyperplasia (albeit at a slower rate) and hypertrophy
simultaneously. Increased a-SMA expression in prolifera-
tive diseases may reflect concurrent hypertrophy and hy-
perplasia in vivo. TGF-b production in diseases could be
responsible. TGF-b is known to stimulate a-SMA synthesis
in smooth muscle cells [44] and fibroblasts [45], and it
causes hypertrophy of rat mesangial cells [46].
Cells in serum-plus medium alone were smallest, but
cells in serum-plus medium with TGF-b1 were largest (even
larger than serum-minus cells with TGF-b1). This suggests
that serum contains a factor or factors that have a syner-
gistic effect on TGF-b1-induced hypertrophy. TGF-b1 in-
creased expression of a-SMA in cells in serum-plus me-
dium but not serum-minus medium. However, the latter
contained more a-SMA, with or without TGF-b1, than cells
in serum-plus medium with TGF-b1. These differences in
the response to TGF-b1 of cells in medium with or without
serum may be due to the presence of a complex mixture of
factors in serum, including some that inhibit a-SMA ex-
pression. The observation that no clear response to TGF-b1
was observed in medium without serum could be due to
Fig. 8. Western blot analysis of a-SMA in
human mesangial cells treated with TGF-b1,
PDGF-BB, thrombin, and/or SFLLRN. Cells
from the experiment described in Figure 7 were
washed and extracted in electrophoresis sample
buffer. More sample was analyzed for cells in
serum-plus medium (1 mg), than for cells in
serum-minus medium (0.2 mg) in order to allow
a more accurate relative quantitation of a-
SMA. Values below bands show the results of
densitometric analysis using the NIH Image
Software. Values in parentheses have been
corrected for differences in the total protein
analyzed.
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absence of serum factors that enhance the responsive-
ness of cells to TGF-b1. From published observations
[47], the concentration of PDGF-BB in 16.7% serum can
be estimated at 1.3 ng/ml. Although the cells were not
responsive to TGF-b1 when serum deprived, TGF-b1
nonetheless antagonized the effect of PDGF-BB (Figs. 7,
8 and 9). This suggests that PDGF-BB may partially
restore TGF-b responsiveness to the serum-deprived
mesangial cells, perhaps through affecting TGF-b1 re-
ceptor expression. Clearly, diverse substances in serum
may alone or in combination be responsible for the effect
of TGF-b1 and serum together on cell size and a-SMA
expression.
Increased expression of a-SMA has been observed in
other cell types undergoing hypertrophy. Hypertrophy of
vascular smooth muscle cells treated in culture with angio-
tensin II or arginine vasopressin is accompanied by a
selective increase in a-SMA expression [50]. During car-
diac hypertrophy in response to increased load caused by
aortic coarctation there is reactivation of a-SMA expres-
sion [51]. Hence, increased a-SMA expression may be a
general manifestation of hypertrophy in cells of mesenchy-
mal origin.
In summary, human mesangial cells deprived of serum
enlarge and develop dense bundles of stress fibers rich in
a-SMA. This process, hypertrophy, was antagonized revers-
ibly by serum, thrombin, and PDGF-BB. TGF-b1 caused
hypertrophy and increased a-SMA expression in the pres-
ence of serum. Diverse factors probably act on mesangial
cells cultured in the presence of serum or in vivo in the
setting of inflammation or sclerosis to regulate the level of
a-SMA expression, but enhanced expression of a-SMA is
primarily reflective of conditions favoring hypertrophy
rather than hyperplasia.
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APPENDIX
Abbreviations used in this article are: a-SMA, a-smooth muscle actin;
f-actin, filamentous actin; FBS, fetal bovine serum; g-actin, globular actin;
GAPD, glyceraldehyde phosphate-3-dehydrogenase; PDGF, platelet de-
rived growth factor; S2, serum-minus cells; S1, serum-plus cells;
SFLLRN, thrombin receptor-activating peptide; TGF-b1, transforming
growth factor-b1.
Fig. 9. Forward light scatter flow cytometry and a-SMA expression in
mesangial cells treated with TGF-b1 and various concentrations of
PDGF-BB. Cells were treated with 10 ng/ml TGF-b1 in RPMI 1640 with or
without 16.7% FBS (serum-plus and serum-minus, respectively) or in
RPMI 1640 containing 1, 2, 4, or 10 ng/ml PDGF-BB. The same protocol
was followed as in Figure 8. The results are the averages of three
experiments. Median forward light scattering and a-SMA band density
were normalized to the values of serum-minus cells (100%) before
averaging. Symbols are: (j) without TGF-b1; (u) with TGF-b1.
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